Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

17.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
17.8K
Hybridoma Technology01:31

Hybridoma Technology

18.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.2K
Transcytosis of IgG01:15

Transcytosis of IgG

4.4K
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Personalised treatment of patients with immune thrombotic thrombocytopenic purpura].

Terapevticheskii arkhiv·2025
Same author

[Removal of a dermoid cyst of the floor of the mouth in a patient with severe hemophilia A].

Stomatologiia·2024
Same author

[The burden of COVID-19 in a heterogeneous population of immunocompromised patients - realities of the postpandemic].

Terapevticheskii arkhiv·2023
Same author

Differences in the Differentiation Potential and Relative Levels of Gene Expression in the Bone Marrow-Derived Fibroblast Colony-Forming Units in Patients during the Onset of Aplastic Anemia Depending on the Disease Severity.

Bulletin of experimental biology and medicine·2023
Same author

Dynamics of Changes in the Properties of Multipotent Mesenchymal Stromal Cells in Patients with Acute Leukemia.

Bulletin of experimental biology and medicine·2023
Same author

COMPARATIVE ANALYSIS OF SEROLOGICAL MARKERS OF HERPES VIRUSES AND QUANTITATIVE IMMUNOGLOBULINOPATHIES IN PRIMARY PATIENTS WITH ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA.

Voprosy virusologii·2022

Related Experiment Video

Updated: Mar 17, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K

[Diffuse large B-cell lymphoma with monoclonal immunoglobulin secretion].

O A Gavrilina1, E N Parovichnikova1, E E Zvonkov1

  • 1National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.

Terapevticheskii Arkhiv
|July 27, 2016
PubMed
Summary

Monoclonal immunoglobulin secretion in diffuse large B-cell lymphoma (DLBCL) is linked to bone marrow involvement and poor prognosis. Intensified therapies offer limited long-term remission for these patients.

More Related Videos

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

19.4K
Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
13:14

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

11.1K

Related Experiment Videos

Last Updated: Mar 17, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K
Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

19.4K
Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
13:14

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

11.1K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
  • Monoclonal immunoglobulin secretion is a distinct subtype of DLBCL.
  • Understanding the characteristics and treatment outcomes of Ig-secreting DLBCL is crucial.

Purpose of the Study:

  • To define the clinical features of DLBCL patients with monoclonal immunoglobulin secretion.
  • To assess the efficacy of intensified treatment regimens (mNHL-BFM-90 or R-DA-EPOCH/R-HMA) in this subgroup.

Main Methods:

  • A clinical trial involving 93 newly diagnosed DLBCL patients.
  • Identification of 21 patients (22.6%) with monoclonal immunoglobulin secretion.
  • Analysis of clinical characteristics, prognostic factors, and survival rates.

Main Results:

  • Ig-secreting DLBCL is significantly associated with bone marrow involvement (p<0.001).
  • These patients often present with advanced stage (Ann Arbor Stage 4) and high International Prognostic Index scores (p=0.001, p=0.026).
  • Overall and event-free survival rates were poorer compared to non-Ig-secreting DLBCL, even with intensified therapy.

Conclusions:

  • Monoclonal paraprotein secretion strongly correlates with bone marrow involvement in DLBCL.
  • Intensified therapy protocols, including autologous stem cell transplantation, do not consistently achieve long-term remission in all Ig-secreting DLBCL patients.
  • Further research is needed to optimize treatment strategies for this challenging DLBCL subtype.